Lantheus

Our LinkedIn community has reached an incredible milestone – 30,000 followers! 🎉      This achievement represents more than just numbers. It reflects a growing network of healthcare professionals, researchers, patients, advocates, stakeholders and innovators who support our Purpose to #FindFightFollow disease to deliver better patient outcomes.       Thank you to our community for engaging, supporting and offering insights as we continue to #GoFurther for patients, providers and more!   

The 2025 Medical Affairs Summit was a success, featuring four days of collaboration – building stronger cross-functional connections across oncology, neurology and radiopharmaceuticals. Under the theme Inventing Tomorrow: One Team, One Dream, our medical affairs community – comprising medical communications, field medical, operations and medical strategy – came together to define the future of Lantheus.  Thank you to everyone for working to strengthen our science and team, and ultimately help us #GoFurther for the patients we serve.    #LeadingRadiopharma #OneLantheus

Meet Keith, a veteran, dedicated husband and cancer advocate, who turned uncertainty into action. Following a life-changing #prostatecancer diagnosis, Keith and his wife, Tracy, faced difficult decisions head on, proving that courage and persistence can alter the course of care.     Keith’s story is a powerful reminder that determination and seeking answers can make all the difference.     Join #Lantheus this month in honoring the strength of patients and families, like Keith and Tracy. Hear Keith’s full story: https://bit.ly/3Isre1E  

#NEWS: Lantheus and GE HealthCare today announced an exclusive licensing agreement for GE HealthCare to develop, manufacture and commercialize Lantheus’ leading PSMA PET imaging agent in Japan for #prostatecancer diagnostics and companion diagnostic use.     GE HealthCare will draw on its extensive manufacturing network and R&D expertise following its acquisition in March 2025 of Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan.    Read the full release: https://lnkd.in/e7EWKBmW     #LeadingRadiopharma 

Come visit us at #ASTRO25! Don’t miss this panel discussion—a case-based presentation with Steven Finkelstein MD FACRO & David Albala, MD. Learn how #Lantheus is advancing #radiopharmaceutical innovation.     We look forward to engaging with the #oncology community and contributing to the important dialogue on how to drive better outcomes in oncology.    View the program here: https://bit.ly/3UvWxes  

Here at #Lantheus, everything is falling into place, as we’re welcoming new colleagues and building momentum towards the future. 🍁🍂 This fall, we’re embracing exciting new chapters and bold ambitions. If you're passionate about radiopharmaceuticals and driven by patient-focused innovation, now’s the perfect time to join us as we #FindFightFollow disease to deliver better patient outcomes. Explore our open roles and take the next step in your journey this fall: https://bit.ly/LNTHCareers #FindFightFollow #LantheusIsHiring

On #WorldAlzheimersDay, we stand alongside our global colleagues Life Molecular Imaging and the broader Alzheimer’s community in raising awareness for one of the most pressing health challenges of our time. #AlzheimersDisease affects millions, placing an immense strain on patients, caregivers and the larger healthcare system. At #Lantheus, we are dedicated to making a difference.  As the leading radiopharmaceutical-focused company, #Lantheus is furthering our impact in neurodegenerative diseases, like #AD, advancing next-generation radiodiagnostic solutions that may help physicians detect disease earlier and deliver more informed decisions.  This work is driven by a single unified Purpose – to #FindFightFollow disease to deliver better patient outcomes for those who need it most.    Learn how we continue to advance the future of neurology: https://bit.ly/4lG88Cz

Tomorrow, our friend Eric will take on Mount Kilimanjaro as part of the inaugural #ZeroPeaksChallenge sponsored by ZERO Prostate Cancer. His journey is a powerful reminder that together, we can reach new heights in improving outcomes for this disease.     Hear more from Eric about what this challenge means to him and why he’s determined to make a difference.

We painted across the globe 🌎 today! Teams from Massachusetts, Germany and New Jersey came together as #OneLantheus to spend the day painting murals at #PaintFest - the Foundation for Hospital Art’s (FFHA) initiative to bring comfort and hope through art to people in healthcare facilities around the world. Thank you to everyone for bringing your creativity and collaboration to this event as we worked together to #FindFightFollow disease to deliver better patient outcomes. 🎨

The #BostonHeartWalk is next month, and #TeamLantheus is getting ready to step out in support of the American Heart Association. We’re proud to walk as #OneLantheus for those impacted by heart disease and stroke, and to help build a healthier future for all. Mark your calendar and get ready to join us. Every step we take moves us closer to stronger hearts and longer lives. Whether you're walking alongside us or cheering us on from afar, thank you for making a difference.    Learn more: 2025 Boston Heart Walk: https://lnkd.in/eanFqNKK